FIGURE 1.

AXL plays a pivotal role in the viability of EGFR‐mutant NSCLC cells treated with lazertinib. (A) EGFR‐mutant NSCLC cell lines PC‐9, HCC4011, H1975, PC‐9GXR, KPP‐03, HCC827, and HCC4006 were incubated with indicated concentrations of lazertinib for 72 h. Cell growth was determined using MTT assays, and the IC₅₀ values of lazertinib for each cell line were determined. *p < 0.05 (B) PC‐9 cell viability after 7 days of treatment with indicated concentrations of lazertinib or gefitinib, replenished every 72 h. (C) MTT assays evaluating the effect of a combination of EGFR inhibitor lazertinib (100 nmol/L) and knockdown of 56 receptor tyrosine kinases from Silencer® Select human kinase siRNA library V4 on PC‐9 cell viability. The 56 RTKs are rank ordered from highest to lowest according to their inhibitory effect on the viability of PC‐9 cells relative to nonspecific control siRNA. (D) PC‐9, HCC4011, H1975, and KPP‐03 cells were treated with nonspecific control siRNA or AXL‐specific siRNAs and were incubated with or without lazertinib (100 nmol/L) for 72 h. Cell viability was detected using MTT assays. *p < 0.05.